You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 28, 2024

~ Buy the KOSELUGO (selumetinib sulfate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR KOSELUGO

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for koselugo

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00551070 ↗	Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer	Completed	NRG Oncology	Phase 2	2007-12-17	This phase II trial studies the side effects and how well selumetinib sulfate works in treating patients with low-grade ovarian cancer that has come back (recurrent). Selumetinib sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT00551070 ↗	Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2007-12-17	This phase II trial studies the side effects and how well selumetinib sulfate works in treating patients with low-grade ovarian cancer that has come back (recurrent). Selumetinib sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT01364051 ↗	Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies	Active, not recruiting	National Cancer Institute (NCI)	Phase 1	2011-05-25	This phase I trial studies the side effects and best dose of cediranib maleate and selumetinib sulfate in treating patients with solid malignancies. Cediranib maleate and selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also stop the growth of tumor cells by blocking blood flow to the tumor.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for koselugo

Condition Name

Chart
Table

Condition Name for koselugo
Intervention	Trials
Refractory Malignant Solid Neoplasm	3
Low Grade Glioma	3
Advanced Malignant Solid Neoplasm	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for koselugo
Intervention	Trials
Neurofibromatosis 1	4
Neurofibromatoses	4
Neurofibroma	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for koselugo

Trials by Country

Map
Table

Trials by Country for koselugo
Location	Trials
United States	226
Puerto Rico	4
Canada	2
China	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for koselugo
Location	Trials
Texas	7
Maryland	7
Alabama	6
Florida	6
Pennsylvania	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for koselugo

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for koselugo
Clinical Trial Phase	Trials
Phase 3	3
Phase 2	7
Phase 1	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for koselugo
Clinical Trial Phase	Trials
Recruiting	6
Not yet recruiting	3
Active, not recruiting	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for koselugo

Sponsor Name

Chart
Table

Sponsor Name for koselugo
Sponsor	Trials
National Cancer Institute (NCI)	10
Merck Sharp & Dohme Corp.	1
AstraZeneca	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for koselugo
Sponsor	Trials
NIH	10
Other	3
Industry	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.